Victory Capital Management Inc. Has $23.29 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Victory Capital Management Inc. lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 96.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 406,811 shares of the biopharmaceutical company’s stock after selling 11,553,666 shares during the period. Victory Capital Management Inc. owned approximately 0.32% of Halozyme Therapeutics worth $23,286,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC raised its holdings in shares of Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 254 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth about $33,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth about $49,000. Toth Financial Advisory Corp acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth about $57,000. Finally, FSC Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth about $65,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 6.7 %

HALO opened at $42.57 on Tuesday. The company has a 50 day moving average of $56.04 and a 200 day moving average of $53.48. The company has a market cap of $5.42 billion, a PE ratio of 14.10, a price-to-earnings-growth ratio of 0.42 and a beta of 1.29. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Morgan Stanley upped their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Benchmark reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. The Goldman Sachs Group upped their price objective on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. Finally, Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $61.11.

Insiders Place Their Bets

In other news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total transaction of $532,600.00. Following the sale, the senior vice president now owns 173,756 shares in the company, valued at approximately $9,254,244.56. This trade represents a 5.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold 70,000 shares of company stock worth $4,042,500 in the last three months. 2.40% of the stock is currently owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.